Meta Pixel

News and Announcements

Aurora Labs Raises $7m to Fast-Track its 3D Printer Business

  • Published February 24, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Aurora Labs (ASX: A3D) have successfully raised funds completed from an oversubscribed share placement to raise $7m at $2.50 per share – to fast-track the development of the company’s 3D printers.

KEY TAKEAWAYS:

  • The Perth-based company are developing a range of metal 3D printers that are cheaper than its competitors.
  • The new funds will be spent to accelerate the development + testing of Aurora’s innovative printers.
  • The company listed on the ASX during August 2016 after successfully raising $2.8m through an IPO.

“Aurora burst into investors’ consciousness late last year when the stock, which listed at $0.20, skyrocketed to a peak of $5.35, giving it a market capitalisation of nearly $300 million. The focus of the exuberance is its large-format 3D metal printer prototype that can be used to make metal parts for a variety of industrial applications. Interestingly, Aurora is in discussions with some of the world’s biggest mining companies to reduce their inventories of spare parts through the use of the company’s 3D metal printer. In December 2016, Aurora shipped itsfirst small S-Titanium Pro printer to a buyer. This marked the company’s transition from a developer to a producer of 3D metal printers.”

Aurora Labs has patent-pending technology that has the potential to revolutionize the manufacturing industry. They have developed the world’s first affordable 3D metal printer which is moving to commercialisation in the next few months. They are in the prototyping and testing phase of their ground breaking large format printer which is expected to print 100 times faster than current competing printers with similar resolution.

Capital Insights
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula

Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.

Join over 45,000+ sophisticated investors

Join Now